recombinant γ-synuclein monomer Search Results


  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 92
    rPeptide recombinant γ synuclein monomer
    Cross-binding competition ELISA assays. a , b , and c : The two site inhibition curves show distinct high and low binding components in plasma from Parkinson’s Disease ( PD-blue, squares ), Multiple System Atrophy ( MSA-green, triangles ) patients and normal control ( NC-black, circles ) subjects. Ten plasma samples from each group were pooled and incubated in 1:400 dilution with increasing concentration of α-, β-, and <t>γ-synuclein</t> monomers in combinations as indicated, with subsequent measurement of free NAbs by ELISA on plates coated with 10 μg/ml of α-synuclein. d - i : Percentage of inhibition (PI) of individual plasma samples with free d , e : α−/β-synuclein monomers, F , G : α−/γ-synuclein monomers; h , i : β−/γ-synuclein monomer on plates coated with 10 μg/mL of α-synuclein monomer. Plasma samples from Parkinson’s Disease (PD), Multiple System Atrophy (MSA) patients and normal controls (NC) were tested at 1:400 dilution in the presence of ( d , f , h ) 100 nM or ( e , g , i ) 10 nM α-, β-, and γ-synuclein monomers in combinations. Horizontal bars represent the mean values +/− SEM. Significance was tested using Man–Whitney’s U test ( P
    Recombinant γ Synuclein Monomer, supplied by rPeptide, used in various techniques. Bioz Stars score: 92/100, based on 4 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/recombinant γ synuclein monomer/product/rPeptide
    Average 92 stars, based on 4 article reviews
    Price from $9.99 to $1999.99
    recombinant γ synuclein monomer - by Bioz Stars, 2020-04
    92/100 stars
      Buy from Supplier

    Image Search Results


    Cross-binding competition ELISA assays. a , b , and c : The two site inhibition curves show distinct high and low binding components in plasma from Parkinson’s Disease ( PD-blue, squares ), Multiple System Atrophy ( MSA-green, triangles ) patients and normal control ( NC-black, circles ) subjects. Ten plasma samples from each group were pooled and incubated in 1:400 dilution with increasing concentration of α-, β-, and γ-synuclein monomers in combinations as indicated, with subsequent measurement of free NAbs by ELISA on plates coated with 10 μg/ml of α-synuclein. d - i : Percentage of inhibition (PI) of individual plasma samples with free d , e : α−/β-synuclein monomers, F , G : α−/γ-synuclein monomers; h , i : β−/γ-synuclein monomer on plates coated with 10 μg/mL of α-synuclein monomer. Plasma samples from Parkinson’s Disease (PD), Multiple System Atrophy (MSA) patients and normal controls (NC) were tested at 1:400 dilution in the presence of ( d , f , h ) 100 nM or ( e , g , i ) 10 nM α-, β-, and γ-synuclein monomers in combinations. Horizontal bars represent the mean values +/− SEM. Significance was tested using Man–Whitney’s U test ( P

    Journal: Molecular Neurodegeneration

    Article Title: Autoimmune antibody decline in Parkinson’s disease and Multiple System Atrophy; a step towards immunotherapeutic strategies

    doi: 10.1186/s13024-017-0187-7

    Figure Lengend Snippet: Cross-binding competition ELISA assays. a , b , and c : The two site inhibition curves show distinct high and low binding components in plasma from Parkinson’s Disease ( PD-blue, squares ), Multiple System Atrophy ( MSA-green, triangles ) patients and normal control ( NC-black, circles ) subjects. Ten plasma samples from each group were pooled and incubated in 1:400 dilution with increasing concentration of α-, β-, and γ-synuclein monomers in combinations as indicated, with subsequent measurement of free NAbs by ELISA on plates coated with 10 μg/ml of α-synuclein. d - i : Percentage of inhibition (PI) of individual plasma samples with free d , e : α−/β-synuclein monomers, F , G : α−/γ-synuclein monomers; h , i : β−/γ-synuclein monomer on plates coated with 10 μg/mL of α-synuclein monomer. Plasma samples from Parkinson’s Disease (PD), Multiple System Atrophy (MSA) patients and normal controls (NC) were tested at 1:400 dilution in the presence of ( d , f , h ) 100 nM or ( e , g , i ) 10 nM α-, β-, and γ-synuclein monomers in combinations. Horizontal bars represent the mean values +/− SEM. Significance was tested using Man–Whitney’s U test ( P

    Article Snippet: 96-well polystyrene microtiter plates (Nunc MaxiSorp® flat-bottom 96 well plate) were coated with either 10 μg/mL recombinant β-synuclein monomer (rPeptide,GA,USA, #S-1003-2) or 10 μg/mL recombinant γ-synuclein monomer (rPeptide,GA,USA, #S-1007-1) in ice-cold 0.1 M carbonate buffer (pH 8.5) overnight ( > 12 h) at 4 °C.

    Techniques: Binding Assay, Enzyme-linked Immunosorbent Assay, Inhibition, Incubation, Concentration Assay

    γ-synuclein competition ELISA assays. a The two site inhibition curves show high and low binding components in pooled plasma samples from Parkinson’s Disease ( PD-blue, squares ), Multiple System Atrophy ( MSA-green, triangles ) patients and normal control ( NC-black, circles ) subjects. 10 μg/mL γ-synuclein coating, plasma dilution 1:400; b and c : Binding of anti-γ-synuclein NAbs in individual plasma samples to immobilized γ-synuclein monomer (10 μg/mL) in competitive ELISA assay in the presence of b 100 nM or c 10 nM free γ-synuclein. Non-specific binding is defined as the binding to the plate in the presence of 1000 nM free γ-synuclein monomer. Maximal binding is defined as the binding observed in the absence of added free γ-synuclein monomer. Plasma samples were tested at 1:400 dilution. Horizontal bars represent the mean values +/− SEM. Significance was tested using Man–Whitney’s U test ( P

    Journal: Molecular Neurodegeneration

    Article Title: Autoimmune antibody decline in Parkinson’s disease and Multiple System Atrophy; a step towards immunotherapeutic strategies

    doi: 10.1186/s13024-017-0187-7

    Figure Lengend Snippet: γ-synuclein competition ELISA assays. a The two site inhibition curves show high and low binding components in pooled plasma samples from Parkinson’s Disease ( PD-blue, squares ), Multiple System Atrophy ( MSA-green, triangles ) patients and normal control ( NC-black, circles ) subjects. 10 μg/mL γ-synuclein coating, plasma dilution 1:400; b and c : Binding of anti-γ-synuclein NAbs in individual plasma samples to immobilized γ-synuclein monomer (10 μg/mL) in competitive ELISA assay in the presence of b 100 nM or c 10 nM free γ-synuclein. Non-specific binding is defined as the binding to the plate in the presence of 1000 nM free γ-synuclein monomer. Maximal binding is defined as the binding observed in the absence of added free γ-synuclein monomer. Plasma samples were tested at 1:400 dilution. Horizontal bars represent the mean values +/− SEM. Significance was tested using Man–Whitney’s U test ( P

    Article Snippet: 96-well polystyrene microtiter plates (Nunc MaxiSorp® flat-bottom 96 well plate) were coated with either 10 μg/mL recombinant β-synuclein monomer (rPeptide,GA,USA, #S-1003-2) or 10 μg/mL recombinant γ-synuclein monomer (rPeptide,GA,USA, #S-1007-1) in ice-cold 0.1 M carbonate buffer (pH 8.5) overnight ( > 12 h) at 4 °C.

    Techniques: Enzyme-linked Immunosorbent Assay, Inhibition, Binding Assay, Competitive ELISA